This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 12:56, 4 July 2011 (Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 12:56, 4 July 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation ()(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | It has been suggested that this article be merged into Loratadine. (Discuss) Proposed since June 2011. |
| Combination of | |
|---|---|
| Pseudoephedrine | Sympathomimetic |
| Loratadine | H1 antagonist |
| Clinical data | |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| (verify) | |
Pseudoephedrine/loratadine (trade names Claritin-D, Clarinase, Clarinase Repetabs) is an orally administered drug combination for the treatment of allergic rhinitis and the common cold. Pseudoephedrine, one of the naturally occurring alkaloids of ephedra, is a sympathomimetic used as a decongestant. It produces its decongestant effect facilitating vasoconstriction and shrinkage of congested mucosa in upper respiratory areas. Loratadine is a long acting H1 histamine antagonist that is less sedating than older substances of the type.
Indications and usage
Clarinase repetabs tablets are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, sneezing, rhinorrhea, pruritus and lacrimation.
Composition
A Clarinase Repetab tablet contains 5 mg loratadine in the tablet coating and 120 mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours.
Interactions, adverse effects and contraindications
Interactions, adverse effects and contraindications are described in more detail in the articles about pseudoephedrine and loratadine.
Interactions
When sympathomimetics are given to patients receiving monoamine oxidase inhibitors (MAO inhibitors), hypertensive reactions, including hypertensive crises may occur. The antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids may be reduced by sympathomimetics. Beta-adrenergic blocking agents may also interact with sympathomimetics. Increase ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis. Antacids increase the rate of pseudoephedrine absorption, kaolin decreases it.
Adverse effects
During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception of insomnia and dry mouth, both of which were commonly reported.
Contraindications
Clarinase is contraindicated in patients receiving MAO inhibitor therapy or within 14 days of discontinuing such treatment and in patients with narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism.
References
- Drugs.com: Claritin-D
- Israel Ministry of Health: Clarinase Repetabs
- Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.
| Decongestants and other nasal preparations (R01) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Topical |
| ||||||||||
| Systemic use: Sympathomimetics | |||||||||||
| |||||||||||